Ndhan.org


Patient Category Recommended Therapy

Contained Casualty Setting

Adults Preferred choices
Gentamicin, 5 mg/kg IM or IV once daily or 2 mg/kg loading dose followed Alternative choices
Doxycycline, 100 mg IV twice daily or 200 mg IV once daily Chloramphenicol, 25 mg/kg IV 4 times daily§ Children\Preferred choices
Streptomycin, 15 mg/kg IM twice daily (maximum daily dose, 2 g) Gentamicin, 2.5 mg/kg IM or IV 3 times daily† Alternative choices
If ,45 kg, give 2.2 mg/kg IV twice daily (maximum, 200 mg/d) Ciprofloxacin, 15 mg/kg IV twice daily‡ Chloramphenicol, 25 mg/kg IV 4 times daily§ Pregnant women Preferred choice
Gentamicin, 5 mg/kg IM or IV once daily or 2 mg/kg loading dose followed
by 1.7 mg/kg IM or IV 3 times daily†
Alternative choices
Doxycycline, 100 mg IV twice daily or 200 mg IV once daily
Ciprofloxacin, 400 mg IV twice daily‡

Mass Casualty Setting and Postexposure Prophylaxis#

Adults Preferred choices
Doxycycline, 100 mg orally twice daily††
Ciprofloxacin, 500 mg orally twice daily‡
Alternative choice
Chloramphenicol, 25 mg/kg orally 4 times daily§**
Children\ Preferred choice
Doxycycline,††
If >45 kg, give adult dosage
If ,45 kg, then give 2.2 mg/kg orally twice daily
Ciprofloxacin, 20 mg/kg orally twice daily
Alternative choices
Chloramphenicol, 25 mg/kg orally 4 times daily§**
Pregnant women¶ Preferred choices
Doxycycline, 100 mg orally twice daily††
Ciprofloxacin, 500 mg orally twice daily
Alternative choices
Chloramphenicol, 25 mg/kg orally 4 times daily§** *These are consensus recommendations of the Working Group on Civilian Biodefense and are not necessarily approved by the Food and Drug Administration. See “Therapy” section for explanations. One antimicrobial agent should be selected. Therapy should be continued for 10 days. Oral therapy should be substituted when patient’s condition improves. IM indicates intramuscularly; IV, intravenously. †Aminoglycosides must be adjusted according to renal function. Evidence suggests that gentamicin, 5 mg/kg IM or IV once daily, would be efficacious in children, although this is not yet widely accepted in clinical practice. Neonates up to 1 week of age and premature infants should receive gentamicin, 2.5 mg/kg IV twice daily. ‡Other fluoroquinolones can be substituted at doses appropriate for age. Ciprofloxacin dosage should not exceed 1 g/d in children. §Concentration should be maintained between 5 and 20 µg/mL. Concentrations greater than 25 µg/mL can cause reversible bone marrow suppression.35,62 \Refer to “Management of Special Groups” for details. In children, ciprofloxacin dose should not exceed 1 g/d, chloramphenicol should not exceed 4 g/d. Children younger than 2 years should not receive chloramphenicol. ¶Refer to “Management of Special Groups” for details and for discussion of breastfeeding women. In neonates, gentamicin loading dose of 4 mg/kg should be given initially.63 #Duration of treatment of plague in mass casualty setting is 10 days. Duration of postexposure prophylaxis to prevent plague infection is 7 days. **Children younger than 2 years should not receive chloramphenicol. Oral formulation available only outside the United States. ††Tetracycline could be substituted for doxycycline.

Source: http://www.ndhan.org/data/agents/Patient%20Category%20Recommended%20Therapy%20-%20Postexposure%20prophylaxis%20recommendations%20for%20pneumonic%20plague.pdf

chem.wsu.edu

SIGMA-ALDRICH MATERIAL SAFETY DATA SHEET Date Printed: 09/18/2008 Date Updated: 06/26/2008 Version 1.5 Section 1 - Product and Company Information Product Name AMPICILLIN SODIUM SALT Product Number A9518 Brand SIAL Company Sigma-Aldrich Address 3050 Spruce Street SAINT LOUIS MO 63103 US Technical Phone: 800-325-5832 Fax: 800-325-5052 Emergency Phone: 314-776-6555 Section 2 - Composition/Informati

Microsoft word - s._rashid_publications

Shirya Rashid PEER-REVIEWED PUBLICATIONS 1. CORTÉS VA, CURTIS DE, SUKUMARAN S,. SHAO X, RASHID S , SMITH AR, REN J , HAMME RE, AGARWAL AK, HORTON JD, GARG A. MOLECULAR MECHANISMS OF HEPATIC STEATOSIS AND INSULIN RESISTANCE IN THE AGPAT2-DEFICIENT MOUSE MODEL OF CONGENITAL GENERALIZED LIPODYSTROPHY. ( CELL METABOLISM , 9:165- 176, 2009). 2. RASHID S , MARCIL M, RUEL I, AND GENES

Copyright © 2010 Health Drug Pdf